Marius Erik Mayerhoefer

List of Publications by Citations

128 papers	3,188 citations	34 h-index	50 g-index
145 ext. papers	4,184 ext. citations	5.3 avg, IF	5.16 L-index

#	Paper	IF	Citations
128	Introduction to Radiomics. *Journal of Nuclear Medicine*, **2020**, 61, 488-495	8.9	167
127	Effects of MRI acquisition parameter variations and protocol heterogeneity on the results of texture analysis and pattern discrimination: an application-oriented study. *Medical Physics*, **2009**, 36, 1236-43	4.4	130
126	Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. *Journal of Nuclear Medicine*, **2014**, 55, 191-7	8.9	113
125	23Na MR imaging at 7 T after knee matrix-associated autologous chondrocyte transplantation preliminary results. *Radiology*, **2010**, 257, 175-84	20.5	91
124	Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. *Clinical Cancer Research*, **2014**, 20, 2984-93	12.9	86
123	Detection of degenerative cartilage disease: comparison of high-resolution morphological MR and quantitative T2 mapping at 3.0 Tesla. *Osteoarthritis and Cartilage*, **2010**, 18, 1211-7	6.2	82
122	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. *Lancet Haematology,the*, **2017**, 4, e595-e606	14.6	74
121	Texture-based and diffusion-weighted discrimination of parotid gland lesions on MR images at 3.0 Tesla. *NMR in Biomedicine*, **2013**, 26, 1372-9	4.4	73
120	Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer. *PLoS ONE*, **2015**, 10, e0140403	3.7	71
119	Texture-based classification of different gastric tumors at contrast-enhanced CT. *European Journal of Radiology*, **2013**, 82, e537-43	4.7	70
118	Texture-based classification of focal liver lesions on MRI at 3.0 Tesla: a feasibility study in cysts and hemangiomas. *Journal of Magnetic Resonance Imaging*, **2010**, 32, 352-9	5.6	70
117	Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients. *Clinical Cancer Research*, **2015**, 21, 2506-13	12.9	64
116	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. *ESMO Open*, **2016**, 1, e000097	6	59
115	Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Scientific Expert Panel. *Radiology*, **2021**, 300, E323-E327	20.5	56
114	Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer. *European Journal of Radiology*, **2010**, 73, 294-9	4.7	54
113	Evaluation of native hyaline cartilage and repair tissue after two cartilage repair surgery techniques with 23Na MR imaging at 7 T: initial experience. *Osteoarthritis and Cartilage*, **2012**, 20, 837-45	6.2	53
112	STIR vs. T1-weighted fat-suppressed gadolinium-enhanced MRI of bone marrow edema of the knee: computer-assisted quantitative comparison and influence of injected contrast media volume and acquisition parameters. *Journal of Magnetic Resonance Imaging*, **2005**, 22, 788-93	5.6	51

111	PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 51-60	8.8	51
110	Shoulder impingement: relationship of clinical symptoms and imaging criteria. *Clinical Journal of Sport Medicine*, **2009**, 19, 83-9	3.2	50
109	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. *Blood*, **2019**, 134, 1132-1143	2.2	46
108	High-resolution cartilage imaging of the knee at 3T: basic evaluation of modern isotropic 3D MR-sequences. *European Journal of Radiology*, **2011**, 78, 398-405	4.7	45
107	Texture analysis for tissue discrimination on T1-weighted MR images of the knee joint in a multicenter study: Transferability of texture features and comparison of feature selection methods and classifiers. *Journal of Magnetic Resonance Imaging*, **2005**, 22, 674-80	5.6	45
106	18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. *Investigative Radiology*,	10.1	44
105	Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3 Tesla. *European Journal of Nuclear Medicine and Molecular Imaging*, **2011**, 38, 1009-19	8.8	43
104	Are signal intensity and homogeneity useful parameters for distinguishing between benign and malignant soft tissue masses on MR images? Objective evaluation by means of texture analysis. *Magnetic Resonance Imaging*, **2008**, 26, 1316-22	3.3	43
103	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. *Blood*, **2017**, 130, 2499-2503	2.2	42
102	A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. *Blood*, **2017**, 129, 383-385	2.2	39
101	Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. *Clinical Nuclear Medicine*, **2017**, 42, 669-674	1.7	39
100	Effects of magnetic resonance image interpolation on the results of texture-based pattern classification: a phantom study. *Investigative Radiology*, **2009**, 44, 405-11	10.1	39
99	The in vivo effects of unloading and compression on T1-Gd (dGEMRIC) relaxation times in healthy articular knee cartilage at 3.0 Tesla. *European Radiology*, **2010**, 20, 443-9	8	38
98	Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. *European Radiology*, **2013**, 23, 1978-85	8	37
97	Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). *Annals of Hematology*, **2014**, 93, 249-53	3	34
96	Short-term outcome of painful bone marrow oedema of the knee following oral treatment with iloprost or tramadol: results of an exploratory phase II study of 41 patients. *Rheumatology*, **2007**, 46, 1460-5	3.9	34
95	Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2760-2769	8.8	33
94	Comparison of MRI and conventional radiography for assessment of acromial shape. *American Journal of Roentgenology*, **2005**, 184, 671-5	5.4	33

93	[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results. *Investigative Radiology*, **2018**, 53, 403-408	10.1	28
92	Sodium MR imaging of Achilles tendinopathy at 7 T: preliminary results. *Radiology*, **2012**, 262, 199-205	20.5	28
91	Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer. *Clinical Nuclear Medicine*, **2019**, 44, 535-543	1.7	28
90	Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis. *Annals of Hematology*, **2014**, 93, 1287-95	3	27
89	Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by F-Fluoride and F-FDG. *Journal of Nuclear Medicine*, **2017**, 58, 968-974	8.9	26
88	Quantitative assessment of atherosclerotic plaques on (18)F-FDG PET/MRI: comparison with a PET/CT hybrid system. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1503-12	8.8	26
87	Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [Ga]Ga-Pentixafor-PET/MRI. *Theranostics*, **2019**, 9, 3653-3658	12.1	26
86	Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients. *PLoS ONE*, **2014**, 9, e104004	3.7	25
85	Quantitative analysis of lumbar intervertebral disc abnormalities at 3.0 Tesla: value of T(2) texture features and geometric parameters. *NMR in Biomedicine*, **2012**, 25, 866-72	4.4	24
84	Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker. *Prostate*, **2015**, 75, 1760-7	4.2	24
83	Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging?. *European Radiology*, **2012**, 22, 2451-7	8	24
82	Diffusion weighted imaging: lymph nodes. *European Journal of Radiology*, **2010**, 76, 398-406	4.7	23
81	Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT. *European Journal of Radiology*, **2010**, 73, 324-8	4.7	22
80	Computer-assisted quantitative analysis of bone marrow edema of the knee: initial experience with a new method. *American Journal of Roentgenology*, **2004**, 182, 1399-403	5.4	22
79	Texture-Based Analysis of 100 MR Examinations of Head and Neck Tumors - Is It Possible to Discriminate Between Benign and Malignant Masses in a Multicenter Trial?. *RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren*, **2016**, 188, 195-202	2.3	22
78	PET/MRI for Oncologic Brain Imaging: A Comparison of Standard MR-Based Attenuation Corrections with a Model-Based Approach for the Siemens mMR PET/MR System. *Journal of Nuclear Medicine*, **2017**, 58, 1519-1525	8.9	21
77	Sustained Response to Vemurafenib in a BRAF-Mutated Anaplastic Thyroid Carcinoma Patient. *Thyroid*, **2016**, 26, 1515-1516	6.2	21
76	11C-methionine PET/CT imaging of 99mTc-MIBI-SPECT/CT-negative patients with primary hyperparathyroidism and previous neck surgery. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 4199-205	5.6	21

75	Non-Invasive Assessment of Breast Cancer Molecular Subtypes with Multiparametric Magnetic Resonance Imaging Radiomics. *Journal of Clinical Medicine*, **2020**, 9,	5.1	19
74	Feasibility of texture analysis for the assessment of biochemical changes in meniscal tissue on T1 maps calculated from delayed gadolinium-enhanced magnetic resonance imaging of cartilage data: comparison with conventional relaxation time measurements. *Investigative Radiology*, **2010**, 45, 543-7	10.1	19
73	[F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 2159-2169	8.8	18
72	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. *European Radiology*, **2021**, 31, 6001-6012	8	16
71	High-resolution magnetic resonance imaging and conventional magnetic resonance imaging on a standard field-strength magnetic resonance system compared to arthroscopy in patients with suspected meniscal tears. *Academic Radiology*, **2008**, 15, 928-33	4.3	15
70	Reproducibility of MRI Dixon-Based Attenuation Correction in Combined PET/MR with Applications for Lean Body Mass Estimation. *Journal of Nuclear Medicine*, **2016**, 57, 1096-101	8.9	14
69	Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients. *Clinical Nuclear Medicine*, **2016**, 41, 837-843	1.7	14
68	Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients. *Clinical Nuclear Medicine*, **2016**, 41, 101-5	1.7	14
67	Ultra-early response assessment in lymphoma treatment: [F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 931-940	8.8	13
66	Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?. *European Radiology*, **2012**, 22, 938-46	8	13
65	Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma. *Oncologist*, **2016**, 21, 72-5	5.7	12
64	Does weight force application to the lower torso have an influence on inferior vena cava and cardiovascular parameters?. *American Journal of Emergency Medicine*, **2008**, 26, 603-7	2.9	12
63	[18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients. *Cancers*, **2020**, 12,	6.6	12
62	Rapid detection of bone metastasis at thoracoabdominal CT: accuracy and efficiency of a new visualization algorithm. *Radiology*, **2014**, 270, 825-33	20.5	11
61	Three-dimensional texture analysis of contrast enhanced CT images for treatment response assessment in Hodgkin lymphoma: comparison with F-18-FDG PET. *Medical Physics*, **2014**, 41, 121904	4.4	11
60	MRI-demonstrated outcome of subchondral stress fractures of the knee after treatment with iloprost or tramadol: observations in 14 patients. *Clinical Journal of Sport Medicine*, **2008**, 18, 358-62	3.2	11
59	Oblique MR imaging of the anterior cruciate ligament based on three-dimensional orientation. *Journal of Magnetic Resonance Imaging*, **2007**, 26, 794-8	5.6	11
58	Texture Bags: Anomaly Retrieval in Medical Images Based on Local 3D-Texture Similarity. *Lecture Notes in Computer Science*, **2012**, 116-127	0.9	11

57	PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype?. *Clinical and Translational Imaging*, **2019**, 7, 405-413	2	10
56	Bone Marrow Involvement in Malignant Lymphoma: Evaluation of Quantitative PET and MRI Biomarkers. *Academic Radiology*, **2018**, 25, 453-460	4.3	10
55	A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. *Hematological Oncology*, **2018**, 36, 49-55	1.3	10
54	Abnormal findings in hallucal sesamoids on MR imaging-Associated with different pathologies of the forefoot? An observational study. *European Journal of Radiology*, **2010**, 74, 226-30	4.7	10
53	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematological Cancers and Identifies Exceptional Responders. *Cancer Discovery*, **2021**,	24.4	10
52	Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT-A trial. *Hematological Oncology*, **2019**, 37, 22-26	1.3	10
51	CXCR4 PET imaging of mantle cell lymphoma using [Ga]Pentixafor: comparison with [F]FDG-PET. *Theranostics*, **2021**, 11, 567-578	12.1	10
50	Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. *Anticancer Research*, **2014**, 34, 6647-54	2.3	10
49	Influence of PET reconstruction technique and matrix size on qualitative and quantitative assessment of lung lesions on [18F]-FDG-PET: A prospective study in 37 cancer patients. *European Journal of Radiology*, **2017**, 90, 20-26	4.7	9
48	Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. *British Journal of Haematology*, **2019**, 186, 448-459	4.5	9
47	Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). *Hematological Oncology*, **2018**, 36, 62-67	1.3	9
46	Gadolinium diethylenetriaminepentaacetate enhancement kinetics in the menisci of asymptomatic subjects: a first step towards a dedicated dGEMRIC (delayed gadolinium-enhanced MRI of cartilage)-like protocol for biochemical imaging of the menisci. *NMR in Biomedicine*, **2011**, 24, 1210-5	4.4	9
45	Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging. *PLoS ONE*, **2016**, 11, e0164118	3.7	9
44	Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. *Leukemia and Lymphoma*, **2016**, 57, 206-8	1.9	8
43	Assessement of rheumatic diseases with computational radiology: current status and future potential. *European Journal of Radiology*, **2009**, 71, 211-6	4.7	8
42	MRI and PET/MRI in hematologic malignancies. *Journal of Magnetic Resonance Imaging*, **2020**, 51, 1325-1336	3.6	8
41	Functional imaging using radiomic features in assessment of lymphoma. *Methods*, **2021**, 188, 105-111	4.6	8
40	Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging. *Journal of Magnetic Resonance Imaging*, **2018**, 47, 1217-1226	5.6	7

39	Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna. *Hematological Oncology*, **2019**, 37, 345-351	1.3	7
38	Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma. *Journal of Clinical Oncology*, **2015**, 33, e130-2	2.2	7
37	Radiomics of high-resolution computed tomography for the differentiation between cholesteatoma and middle ear inflammation: effects of post-reconstruction methods in a dual-center study. *European Radiology*, **2021**, 31, 4071-4078	8	7
36	Pre-Therapeutic Total Lesion Glycolysis on [F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy. *Molecular Imaging and Biology*, **2019**, 21, 1192-1199	3.8	6
35	Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. *Cancers*, **2020**, 12,	6.6	6
34	Gender Aspects in Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue: Does Sex Matter?. *Oncology*, **2016**, 91, 243-250	3.6	6
33	Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI. *Clinical Nuclear Medicine*, **2021**, 46, 16-20	1.7	6
32	(18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas. *Anticancer Research*, **2014**, 34, 791-5	2.3	6
31	Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. *Hematological Oncology*, **2017**, 35, 177-186	1.3	5
30	Visceral Pleural Invasion in Pulmonary Adenocarcinoma: Differences in CT Patterns between Solid and Subsolid Cancers. *Radiology: Cardiothoracic Imaging*, **2019**, 1, e190071	8.3	5
29	A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma. *Surgical Endoscopy and Other Interventional Techniques*, **2016**, 30, 2879-85	5.2	5
28	Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma. *Wiener Klinische Wochenschrift*, **2020**, 132, 467-474	2.3	5
27	Positive selection as the unifying force for clonal evolution in multiple myeloma. *Leukemia*, **2021**, 35, 1511-1515	10.7	5
26	Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum. *Case Reports in Oncology*, **2018**, 11, 239-245	1	4
25	F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 3268-3276	8.8	4
24	Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. *Pathology*, **2021**, 53, 385-399	1.6	4
23	Combination of Radiomics and Machine Learning with Diffusion-Weighted MR Imaging for Clinical Outcome Prognostication in Cervical Cancer. *Tomography*, **2021**, 7, 344-357	3.1	4
22	Diffusion-weighted MRI for lymphoma staging--response. *Clinical Cancer Research*, **2015**, 21, 222-3	12.9	3

21	Does elevated glucose metabolism correlate with higher cell density in Neurofibromatosis type 1 associated peripheral nerve sheath tumors?. *PLoS ONE*, **2017**, 12, e0189093	3.7	3
20	Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells. *Frontiers in Immunology*, **2021**, 12, 666935	8.4	3
19	Whole-Body [F]FDG-PET/MRI vs. [F]FDG-PET/CT in Malignant Melanoma. *Molecular Imaging and Biology*, **2020**, 22, 739-744	3.8	3
18	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1522-1537	8.8	3
17	Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study. *PLoS ONE*, **2019**, 14, e0213551	3.7	2
16	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. *Cancer Immunology Research*, **2020**, 8, 984-989	12.5	2
15	DWI-MRI vs CT in gastric MALT lymphoma-preliminary results in 19 patients. *British Journal of Radiology*, **2018**, 20180263	3.4	2
14	RECIL versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. *Cancers*, **2019**, 12,	6.6	2
13	Accuracy of PET quantification in [Ga]Ga-pentixafor PET/MR imaging of carotid plaques. *Journal of Nuclear Cardiology*, **2020**, 1	2.1	2
12	The role of 18F-FDG PET/CT radiomics in lymphoma. *Clinical and Translational Imaging*, **2021**, 9, 589	2	2
11	CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line H. pylori eradication. *Blood*, **2021**,	2.2	2
10	Heavy black tea consumption and elevated CA 19-9 and CA 125 levels. A case report on a patient with ovarian endometriotic cysts. *Gynecological Endocrinology*, **2019**, 35, 478-480	2.4	1
9	Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R: A case report. *Medicine (United States)*, **2016**, 95, e4237	1.8	1
8	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. *Blood*, **2019**, 134, 3965-3965	2.2	1
7	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. *Blood*, **2020**, 136, 2-4	2.2	1
6	First Line Systemic Treatment for MALT Lymphoma-Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna. *Cancers*, **2020**, 12,	6.6	1
5	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. *Blood*, **2019**, 134, 4037-4037	2.2	0
4	Diffusion-Weighted MRI for Lymphoma Restaging--Response. *Clinical Cancer Research*, **2015**, 21, 3809	12.9	

3	Metabolic Tumor Volume and Total Lesion Glycolysis Can Predict Response to Very Low Dose Radiotherapy (4 Gy) in Indolent B-Cell Lymphomas. *Blood*, **2021**, 138, 3518-3518	2.2
2	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. *Blood*, **2017**, 130, 855-855	2.2
1	In Human Visualization of Ibrutinib-Induced CLL Compartment Shift. *Blood*, **2019**, 134, 1750-1750	2.2